 | Sands BE, Winston
BD, Salzberg B, Safdi M, Barish C, Wruble L, Wilkins R, Shapiro M,
Schwertschlag US, and the rhIL-11 Crohn's Study Group. Randomized,
controlled trial of recombinant human interleukin-11 in patients
with active Crohn's disease. Aliment Pharmacol Ther
2002;16:399-406. |
|
| Sands BE,
Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan
SR, Podolsky DK. Infliximab in the treatment of severe,
steroid-refractory ulcerative colitis: a pilot study. Inflammatory
Bowel Diseases 2001; 7(2):83-88. |
|
| Sands BE. Therapy
of inflammatory bowel disease. Gastroenterology 2000; 118(2
Suppl 1):S68-82. |
|
| Sands BE. Novel
therapies for inflammatory bowel disease. Gastroenterology
Clinics of
North America
. 1999;
28(2):323-51 |
|
| Sands BE, Bank S,
Sninsky CA, Robinson M, Katz S, Singleton JW, Miner PB, Safdi MA,
Galandiuk S, Hanauer SB, Varilek GW, Buchman AL, Rodgers VD,
Salzberg B, Cai B, Loewy J, DeBruin MF, Rogge H, Shapiro M,
Schwertschlag US. Preliminary evaluation of safety and activity of
recombinant human interleukin 11 in patients with active Crohn's
disease. Gastroenterology 1999; 117(1):58-64. |
|
|
IBD Watch®
